Human tolerogenic dendritic cells generated with protein kinase C inhibitor are optimal for functional regulatory T cell induction - A comparative study

被引：27

作者：

Adnan, Endy ^{[1
]}

Matsumoto, Takuya ^{[1
]}

Ishizaki, Jun ^{[1
]}

Onishi, Sachiko ^{[1
]}

Suemori, Koichiro ^{[1
]}

Yasukawa, Masaki ^{[1
]}

Hasegawa, Hitoshi ^{[1
]}

机构：

[1] Ehime Univ, Grad Sch Med, Dept Hematol Clin Immunol & Infect Dis, Toon, Ehime 7910295, Japan

来源：

CLINICAL IMMUNOLOGY | 2016年 / 173卷

关键词：

Dendritic cells; Tolerance; Protein kinase C inhibitor; Regulatory T cells; PROLIFERATOR-ACTIVATED-RECEPTOR; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CLASSIFICATION CRITERIA; MATURATION; DIFFERENTIATION; MOLECULES; VITAMIN-D-3; MODULATION; TOLERANCE; CCR7;

D O I：

10.1016/j.clim.2016.09.007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Tolerogenic dendritic cells (tDCs) are a promising therapeutic tool for specific induction of immunological tolerance. Human tDCs can be generated ex vivo using various compounds. However, the compound(s) most suitable for clinical application remain undefined. We compared the tolerogenic properties of tDCs treated with protein kinase C inhibitor (PKCI), dexamethasone, vitamin D3 (Vit D3), rapamycin (Rapa), interleukin (IL)-10, transforming growth factor (TGF)-beta, and a combination of peroxisome proliferator-activated receptor gamma agonist and retinoic acid. All tDCs had a semi-mature DC phenotype. PKCI-, TGF-beta-, and Rapa-tDCs showed CCR7 expression and migration to CCL19, but other tDCs showed little or none. PKCI-and IL-10-tDCs induced functional regulatory T cells more strongly than other tDCs. The tolerogenic properties of all tDCs were stable against proinflammatory stimuli. Furthermore, PKCI-tDCs were generated from patients with rheumatoid arthritis and primary Sjogren's syndrome. Therefore, PKCI-tDCs showed the characteristics best suited for tolerance-inducing therapy. (C) 2016 Elsevier Inc. All rights reserved.

引用

页码：96 / 108

页数：13

共 51 条

[1] 2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative [J].

Aletaha, Daniel ;

Neogi, Tuhina ;

Silman, Alan J. ;

Funovits, Julia ;

Felson, David T. ;

Bingham, Clifton O., III ;

Birnbaum, Neal S. ;

Burmester, Gerd R. ;

Bykerk, Vivian P. ;

Cohen, Marc D. ;

Combe, Bernard ;

Costenbader, Karen H. ;

Dougados, Maxime ;

Emery, Paul ;

Ferraccioli, Gianfranco ;

Hazes, Johanna M. W. ;

Hobbs, Kathryn ;

Huizinga, Tom W. J. ;

Kavanaugh, Arthur ;

Kay, Jonathan ;

Kvien, Tore K. ;

Laing, Timothy ;

Mease, Philip ;

Menard, Henri A. ;

Moreland, Larry W. ;

Naden, Raymond L. ;

Pincus, Theodore ;

Smolen, Josef S. ;

Stanislawska-Biernat, Ewa ;

Symmons, Deborah ;

Tak, Paul P. ;

Upchurch, Katherine S. ;

Vencovsky, Jiri ;

Wolfe, Frederick ;

Hawker, Gillian .

ARTHRITIS AND RHEUMATISM, 2010, 62 (09) :2569-2581

[2] Retinoic acid primes human dendritic cells to induce gut-homing, IL-10-producing regulatory T cells [J].

Bakdash, G. ;

Vogelpoel, L. T. C. ;

van Capel, T. M. M. ;

Kapsenberg, M. L. ;

de Jong, E. C. .

MUCOSAL IMMUNOLOGY, 2015, 8 (02) :265-278

[3]

Bell G.M., 2016, Ann Rheum Dis

[4] Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients [J].

Benham, Helen ;

Nel, Hendrik J. ;

Law, Soi Cheng ;

Mehdi, Ahmed M. ;

Street, Shayna ;

Ramnoruth, Nishta ;

Pahau, Helen ;

Lee, Bernett T. ;

Ng, Jennifer ;

Brunck, Marion E. G. ;

Hyde, Claire ;

Trouw, Leendert A. ;

Dudek, Nadine L. ;

Purcell, Anthony W. ;

O'Sullivan, Brendan J. ;

Connolly, John E. ;

Paul, Sanjoy K. ;

Le Cao, Kim-Anh ;

Thomas, Ranjeny .

SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (290)

[5] IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction - A comparative study of human clinical-applicable DC [J].

Boks, Martine A. ;

Kager-Groenland, Judith R. ;

Haasjes, Michiel S. P. ;

Zwaginga, Jaap Jan ;

van Ham, S. Marieke ;

ten Brinke, Anja .

CLINICAL IMMUNOLOGY, 2012, 142 (03) :332-342

[6] It's Time to Bring Dendritic Cell Therapy to Type 1 Diabetes [J].

Creusot, Remi J. ;

Giannoukakis, Nick ;

Trucco, Massimo ;

Clare-Salzler, Michael J. ;

Fathman, C. Garrison .

DIABETES, 2014, 63 (01) :20-30

[7] Retinoic acid-producing, ex-vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B lymphocytes [J].

Di Caro, V. ;

Phillips, B. ;

Engman, C. ;

Harnaha, J. ;

Trucco, M. ;

Giannoukakis, N. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 174 (02) :302-317

[8] Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction [J].

Fedoric, Boris ;

Krishnan, Ravi .

IMMUNOLOGY LETTERS, 2008, 120 (1-2) :49-56

[9] CCR7 and its ligands:: balancing immunity and tolerance [J].

Foerster, Reinhold ;

Davalos-Misslitz, Ana Clara ;

Rot, Antal .

NATURE REVIEWS IMMUNOLOGY, 2008, 8 (05) :362-371

[10] Physiological concentrations of transforming growth factor β1 selectively inhibit human dendritic cell function [J].

Fogel-Petrovic, MiIjana ;

Long, Julie A. ;

Misso, Neil L. ;

Foster, Paul S. ;

Bhoola, Kanti D. ;

Thompson, Philip J. .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2007, 7 (14) :1924-1933

← 1 2 3 4 5 6 →